Perspectum Completes $19 Million Series C Funding Close

Perspectum has completed the second close of its $55 million Series C funding round, bringing the total amount raised since inception to roughly $140 million. Oppenheimer led the additional $19 million investment.    
 
Since the beginning of 2021, 77 million U.S. adults covered by Medicare and commercial plans have had access to LiverMultiScan, the company’s flagship diagnostic tool to assess and monitor chronic liver disease. The coverage and established reimbursement codes have fueled LiverMultiScan’s adoption by several major U.S. hospitals. Perspectum is working to expand its U.S. footprint and to scale to meet the increasing demands for assessing organ health. 
 
“The second Series C second close further supports deployment, development and validation of our platform-based product portfolio targeted for clinical research and clinical use,” Perspectum CEO Rajarshi Banerjee, M.D., Ph.D., said. “More broadly, it enables us to maintain our demonstrated leadership in the fields of medical AI techs to influence patient care both now and in the future.”  
 
Perspectum’s software products enhance the capabilities of a standard magnetic resonance imaging (MRI) machine, enabling it to capture multiparametric mapping data that allows its AI-driven software to measure organ inflammation with greater precision, aiding diagnosis and the monitoring of patients with chronic diseases.  
 
“When I think of all the patients I cared for over 45 plus years, how I wish I had Perspectum’s AI-enabled technologies in my day,” said Dr. Elizabeth Fagan, Perspectum board member, and adjunct professor of Internal Medicine and Pediatrics at Rush-Presbyterian-St. Luke’s Medical Center, Chicago. “I can see, for example, how Perspectum’s LiverMultiScan combined with their FDA-approved MRCP+ technology can be applied to many chronic liver and biliary diseases.”
 
In addition to scaling its U.S. operations, Perspectum will use the new funding to accelerate its product pipeline for multiorgan conditions and oncology.  
 
“I am thrilled with this second close as Perspectum moves toward mainstream adoption of its current commercially available products such as its flagship LiverMultiScan product,” Perspectum Board Chair Dr. Michael Rosenblatt stated. “The funding supports a more accelerated approach as Perspectum moves to achieve its ultimate goal of standardizing the use of integrated AI clinical decision support tools for the management of patient health at scale globally.”
 
Perspectum, a global medical technology company with offices in the United States, United Kingdom, Portugal, and Singapore, delivers digital technologies that help provide better care for chronic metabolic diseases, multi-organ pathology, and cancer. With a strong focus on precision medicine using advanced imaging and genetics, the company aims to empower patients and clinicians through quantitative assessments of health enabling early detection, diagnosis, and targeted treatment.